#China #Hong Kong #Innovative Drugs #Sino Biopharmaceutical #SBP Group

Sino Biopharmaceutical Limited Launches SBP Group

Sino Biopharmaceutical Limited, a leading innovator in China's pharmaceutical industry, has recently introduced its new global brand, SBP Group, during their half-year results presentation. This initiative marks a significant step in speeding up their international expansion and solidifying their position as a global investor. SBP stands for Science, Breakthroughs, and Patients, encapsulating the company’s dedication to scientific innovation and patient care.

A New Identity for Global Reach

The establishment of SBP Group signifies a transformative shift from being a domestic biopharmaceutical leader to a global innovator in healthcare solutions. This new identity not only underscores Sino Biopharmaceutical’s ambition but also aligns with its mission: “Science for a healthier world.” The company aims to develop a global pipeline of innovative drugs through both in-house research and development as well as strategic acquisitions, which are essential for a successful globalization strategy.

Through its strategic approach, Sino Biopharmaceutical is looking to manage two facets simultaneously—the globalization of its product offerings and its business operations. The company is engaging in partnerships globally and is keen on expanding directly into major international markets. By investing in global talent and enhancing its organizational capabilities, Sino Biopharmaceutical strives to make innovative medicines accessible to more patients across the globe.

Strategic Partnerships and Prominent Deals

In a statement made by the chairwoman, Theresa Tse, she emphasized that 2026 is a pivotal year in the implementation of their globalization strategy. The SBP Group is actively looking to collaborate with international partners to expedite the development and availability of innovative drugs originated from China while also importing cutting-edge therapies from around the world.

So far, Sino Biopharmaceutical has successfully completed four licensing agreements with multinational companies, with upfront payments exceeding $1 billion and a potential total deal value surpassing $7 billion. Notable transactions in 2026 include:

• - An exclusive licensing agreement with Sanofi for Rovadicitinib, a first-in-class dual JAK/ROCK inhibitor, valued at up to $1.53 billion.
• - An exclusive licensing agreement with AstraZeneca for TQC3721, an inhalable PDE3/4 inhibitor aimed at treating COPD, valued at up to $1.9 billion.

These significant deals highlight the company’s capability to not only generate substantial financial commitments but also build a pipeline that could potentially redefine treatment paradigms in various therapeutic areas.

The Comprehensive Portfolio and Future Aspirations

Sino Biopharmaceutical Limited, upon adopting the identity of SBP Group, showcases its comprehensive strengths throughout the value chain, which includes research, development, manufacturing, and marketing. Their product portfolio is diverse, encompassing a range of biologics and small molecule drugs, with leadership in four core therapeutic areas: oncology, liver and cardiometabolic diseases, respiratory and autoimmune diseases, and surgical and analgesic medicine.

The company is committed to continuous expansion and improvement, leveraging artificial intelligence and an integrated platform to push boundaries in scientific research and innovation. Their overarching goal remains clear: to enhance human health by increasing access to innovative medicines.

As the pharmaceutical landscape evolves, Sino Biopharmaceutical's dedication to fostering global partnerships and developing groundbreaking therapies positions it favorably within the international market. Through the SBP Group, the company is poised to not only contribute to healthcare advancements but also redefine its role in the global pharmaceutical industry.